Dark Blue Therapeutics
Research and experimental development on biotechnology.
Incorporated in July 2020
Origin: Oxford University, Oncology
Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.
Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
Big data and analysis company focused on enabling reproducibility in chemistry.
Incorporated in June 2006
Origin: Oxford University
DeepReason.ai offers a Knowledge Graph Management System that can integrate seamlessly with various enterprise, and public, data sources to perform fast and intelligent reasoning
Incorporated in January 2018
Origin: Oxford University, Department of Computer Science
Contact: Adrian Coles
Deontics is software which guides doctors and patients through the scientific and clinical decision making.
Incorporated in August 2014
Origin: Oxford University, Department of Engineering Science
Designer Carbon Materials, Developing advanced nanomaterials for a range of applications, including energy harvesting, bio-sensing and quantum nanoelectronics.
Incorporated in April 2014
Origin: Oxford University, Department of Materials
DiffBlue is a world leader in automated test generation. Their products have been developed with industry partners over the last ten years and replace the manual process of writing tests.
Incorporated in March 2016
Origin: Oxford University, Department of Computer Science
Company developing AI-based learning support applications.
Incorporated in August 2018
Origin: Oxford University, Department of Computer Science
EKB Technology commercialises a revolutionary Bioprocessing Technology developed for the use of biological systems such as plant and animal cells and microorganisms to modify, produce or purify chemical intermediates.
Origin: Oxford University, Department of Earth Sciences
The company has been created by the Dementia Discovery Fund. The Company’s mission is to develop disease-modifying therapeutics that restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease and other dementias.
Origin: Oxford University, Department of Physiology, Anatomy and Genetics
EnzBond aims to change the current understanding of enzyme evolution process.
Incorporated in November 2016
Origin: Oxford University, Department of Chemistry
EvOx Therapeutics harnesses the body’s own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable including those affecting the brain, as well as autoimmune diseases and cancers.
Incorporated in April 2016
Origin: Oxford University, Neuroscience
Energy from Fusion.
Incorporated in July 2011
Origin: Oxford University, Department of Engineering Science
A new approach to automatic speech recognition technology.
Incorporated in February 2024
Origin: Oxford University
Revolutionising the production of Fluorochemicals. A highly innovative, cost-effective and sustainable technology that removes the hazards of traditional fluorinating processes and supply chain.
Incorporated in September 2022
Origin: Oxford University, Chemistry
Eykona develops state-of-the-art imaging solutions to capture dermal characteristics and shape from the human body.
Incorporated in February 2007
Origin: Oxford University, Department of Engineering Science
G-Nostics has identified SNPs that have highly predictive associations with nicotine addiction and therefore tobacco consumption. These SNPs provide a method to help individuals decide which specific smoking cessation methods are most effective for them, offering personalised treatment to the 'smoker' which significantly increases their chances of quitting.
Origin: Oxford University, Sir William Dunn School of Pharmacology
Improving the lives of people living with Parkinson’s.
Incorporated in March 2020
Origin: Oxford University, Department of Physiology, Anatomy and Genetics
Develop cutting edge software applications that uncover the relationships between genetic variation and human disease.
Help pharmaceutical companies de-risk the drug development process.
Incorporated in March 2014
Origin: Oxford University, Wellcome Trust Centre for Human Genetics